Low levels of astroglial markers in Parkinson's disease: Relationship to α-synuclein accumulation

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 243-253

  Tong, Junchao ^a   Ang, Lee Cyn ^b   Williams, Belinda ^a   Furukawa, Yoshiaki ^c   Fitzmaurice, Paul ^d   Guttman, Mark ^e   Boileau, Isabelle ^a   Hornykiewicz, Oleh ^f   Kish, Stephen J ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d The Drug Detection Agency   (New Zealand)

^e Movement Disorders Centre   (Canada)

^f Medical University of Vienna   (Austria)

Author keywords

Astrogliosis; Glial fibrillary acidic protein; Heat shock protein 27; Multiple system atrophy; Parkinson's disease; Progressive supranuclear palsy; Quantitative Western blot; Substantia nigra; Vimentin; synuclein

Indexed keywords

ALPHA SYNUCLEIN; BRAIN PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; HEAT SHOCK PROTEIN 27; VIMENTIN; BIOLOGICAL MARKER; HSPB1 PROTEIN, HUMAN;

AGED; ARTICLE; ASTROCYTOSIS; AUTOPSY; BRAIN HOMOGENATE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOREACTIVITY; MACROGLIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PUTAMEN; QUANTITATIVE ANALYSIS; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA; ASTROCYTE; COMPARATIVE STUDY; FRONTAL LOBE; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING;

AGED; ASTROCYTES; BIOMARKERS; BLOTTING, WESTERN; CAUDATE NUCLEUS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FRONTAL LOBE; GLIAL FIBRILLARY ACIDIC PROTEIN; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; PUTAMEN; SUPRANUCLEAR PALSY, PROGRESSIVE; VIMENTIN;

EID: 84933521678     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.06.010     Document Type: Article

References (85)

1. Adams R.D., Vanbogaert L., Vandereecken H. Striato-nigral degeneration. J. Neuropathol. Exp. Neurol. 1964, 23:584-608.
2. Banati R.B., Daniel S.E., Blunt S.B. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 1998, 13:221-227.
3. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
4. Bousset L., Pieri L., Ruiz-Arlandis G., Gath J., Jensen P.H., Habenstein B., et al. Structural and functional characterization of two alpha-synuclein strains. Nat. Commun. 2013, 4:2575.
5. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
6. Braak H., Sastre M., Del Tredici K. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol. 2007, 114:231-241.
7. Braidy N., Gai W.P., Xu Y.H., Sachdev P., Guillemin G.J., Jiang X.M., et al. Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts. Transl. Neurodegener. 2013, 2:20.
8. Bruck D., Wenning G.K., Stefanova N., Fellner L. Glia and alpha-synuclein in neurodegeneration: A complex interaction. Neurobiol. Dis. 2015, [Epub ahead of print].
9. Charron G., Doudnikoff E., Canron M.H., Li Q., Vega C., Marais S., et al. Astrocytosis in parkinsonism: considering tripartite striatal synapses in physiopathology?. Front. Aging Neurosci. 2014, 6:258.
10. Chen P.C., Vargas M.R., Pani A.K., Smeyne R.J., Johnson D.A., Kan Y.W., et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2933-2938.
11. Choi D.K., Pennathur S., Perier C., Tieu K., Teismann P., Wu D.C., et al. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci. 2005, 25:6594-6600.
12. Colangelo A.M., Alberghina L., Papa M. Astrogliosis as a therapeutic target for neurodegenerative diseases. Neurosci. Lett. 2014, 565:59-64.
13. Damier P., Hirsch E.C., Zhang P., Agid Y., Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993, 52:1-6.
14. Damier P., Kastner A., Agid Y., Hirsch E.C. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?. Neurology 1996, 46:1262-1269.
15. Earle K.M. Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. J. Neuropathol. Exp. Neurol. 1968, 27:1-14.
16. Ehringer H., Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menches und ihr verhalten bei erkrankungen des extrapyramiden systems. Klin. Wochenschr. 1960, 38:1236-1239.
17. Eng L.F., Ghirnikar R.S. GFAP and astrogliosis. Brain Pathol. 1994, 4:229-237.
18. Fellner L., Irschick R., Schanda K., Reindl M., Klimaschewski L., Poewe W., et al. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 2013, 61:349-360.
19. Fellner L., Jellinger K.A., Wenning G.K., Stefanova N. Glial dysfunction in the pathogenesis of alpha-synucleinopathies: emerging concepts. Acta Neuropathol. 2011, 121:675-693.
20. Forno L.S. Pathology of parkinsonism. A preliminary report of 24 cases. J. Neurosurg. 1966, 24:266-279. (Suppl.).
21. Forno L.S. Pathology of Parkinson's disease: the importance of the substantia nigra and Lewy bodies. Parkinson's disease 1990, Chapman and Hall Medical, Stern, London. M. Gerald (Ed.).
22. Forno L.S., DeLanney L.E., Irwin I., Di Monte D., Langston J.W. Astrocytes and Parkinson's disease. Prog. Brain Res. 1992, 94:429-436.
23. Gilman S., Low P.A., Quinn N., Albanese A., Ben-Shlomo Y., Fowler C.J., et al. Consensus statement on the diagnosis of multiple system atrophy. J. Neurol. Sci. 1999, 163:94-98.
24. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
25. Greenfield J.G., Bosanquet F.D. The brain-stem lesions in Parkinsonism. J. Neurol. Neurosurg. Psychiatry 1953, 16:213-226.
26. Greffard S., Verny M., Bonnet A.M., Seilhean D., Hauw J.J., Duyckaerts C. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol. Aging 2010, 31:99-103.
27. Gu X.L., Long C.X., Sun L., Xie C., Lin X., Cai H. Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol. Brain 2010, 3:12.
28. Halliday G.M., Stevens C.H. Glia: initiators and progressors of pathology in Parkinson's disease. Mov. Disord. 2011, 26:6-17.
29. Hassler R. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J. Psychol. Neurol. 1938, 48:387-476.
30. Hassler R. Extrapyramidal-motorische syndrome und erkrankungen. Hb.Inn.Med. 1953, vol. V, part III:822. Springer, Berlin, Göttingen, Heidelberg. G.V. Bergmann, W. Frey, H. Schwiegh, R. Jung (Eds.).
31. Hauw J.J., Daniel S.E., Dickson D., Horoupian D.S., Jellinger K., Lantos P.L., et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994, 44:2015-2019.
32. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
33. Hirsch E.C., Hunot S., Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord. 2005, 11(Suppl. 1):S9-S15.
34. Hishikawa N., Hashizume Y., Yoshida M., Sobue G. Widespread occurrence of argyrophilic glial inclusions in Parkinson's disease. Neuropathol. Appl. Neurobiol. 2001, 27:362-372.
35. Jellinger K.A. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov. Disord. 2012, 27:8-30.
36. Kamo H., Haebara H., Akiguchi I., Kameyama M., Kimura H., McGeer P.L. A distinctive distribution of reactive astroglia in the precentral cortex in amyotrophic lateral sclerosis. Acta Neuropathol. 1987, 74:33-38.
37. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 1988, 318:876-880.
38. Klegeris A., Giasson B.I., Zhang H., Maguire J., Pelech S., McGeer P.L. Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J. 2006, 20:2000-2008.
39. Knott C., Wilkin G.P., Stern G. Astrocytes and microglia in the substantia nigra and caudate-putamen in Parkinson's disease. Parkinsonism Relat. Disord. 1999, 5:115-122.
40. Koob A.O., Paulino A.D., Masliah E. GFAP reactivity, apolipoprotein E redistribution and cholesterol reduction in human astrocytes treated with alpha-synuclein. Neurosci. Lett. 2010, 469:11-14.
41. Kovacs G.G., Breydo L., Green R., Kis V., Puska G., Lorincz P., et al. Intracellular processing of disease-associated alpha-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiol. Dis. 2014, 69:76-92.
42. Kovacs G.G., Milenkovic I.J., Preusser M., Budka H. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit. Mov. Disord. 2008, 23:1608-1612.
43. Kraft A.W., Hu X., Yoon H., Yan P., Xiao Q., Wang Y., et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J. 2013, 27:187-198.
44. Kurowska Z., Englund E., Widner H., Lindvall O., Li J.Y., Brundin P. Signs of degeneration in 12-22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease. J. Parkinsons Dis. 2011, 1:83-92.
45. Lastres-Becker I., Ulusoy A., Innamorato N.G., Sahin G., Rabano A., Kirik D., et al. alpha-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Hum. Mol. Genet. 2012, 21:3173-3192.
46. Marchetti B., L'Episcopo F., Morale M.C., Tirolo C., Testa N., Caniglia S., et al. Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/beta-catenin signaling cascade as the common final pathway for neuroprotection and self-repair. Eur. J. Neurosci. 2013, 37:1550-1563.
47. Maroteaux L., Campanelli J.T., Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 1988, 8:2804-2815.
48. Marxreiter F., Ettle B., May V.E., Esmer H., Patrick C., Kragh C.L., et al. Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice. Neurobiol. Dis. 2013, 59:38-51.
49. McGann J.C., Lioy D.T., Mandel G. Astrocytes conspire with neurons during progression of neurological disease. Curr. Opin. Neurobiol. 2012, 22:850-858.
50. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
51. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord. 2008, 23:474-483.
52. McGeer P.L., McGeer E.G. History of innate immunity in neurodegenerative disorders. Front. Pharmacol. 2011, 2:77.
53. Middeldorp J., Kamphuis W., Sluijs J.A., Achoui D., Leenaars C.H., Feenstra M.G., et al. Intermediate filament transcription in astrocytes is repressed by proteasome inhibition. FASEB J. 2009, 23:2710-2726.
54. Miklossy J., Doudet D.D., Schwab C., Yu S., McGeer E.G., McGeer P.L. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp. Neurol. 2006, 197:275-283.
55. Mirza B., Hadberg H., Thomsen P., Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 2000, 95:425-432.
56. Mori F., Tanji K., Yoshimoto M., Takahashi H., Wakabayashi K. Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp. Neurol. 2002, 176:98-104.
57. Mullett S.J., Hinkle D.A. DJ-1 knock-down in astrocytes impairs astrocyte-mediated neuroprotection against rotenone. Neurobiol. Dis. 2009, 33:28-36.
58. Mythri R.B., Venkateshappa C., Harish G., Mahadevan A., Muthane U.B., Yasha T.C., et al. Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem. Res. 2011, 36:1452-1463.
59. Ozawa T., Paviour D., Quinn N.P., Josephs K.A., Sangha H., Kilford L., et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 2004, 127:2657-2671.
60. Paulus W., Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1991, 50:743-755.
61. Renkawek K., Stege G.J., Bosman G.J. Dementia, gliosis and expression of the small heat shock proteins hsp27 and alpha B-crystallin in Parkinson's disease. Neuroreport 1999, 10:2273-2276.
62. Riley R.A. An atlas of the basal ganglia, brain stem and spinal cord 1943, The Williams & Wilkins Company, Baltimore, MD.
63. Sathe K., Maetzler W., Lang J.D., Mounsey R.B., Fleckenstein C., Martin H.L., et al. S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-alpha pathway. Brain 2012, 135:3336-3347.
64. Schmidt S., Linnartz B., Mendritzki S., Sczepan T., Lubbert M., Stichel C.C., et al. Genetic mouse models for Parkinson's disease display severe pathology in glial cell mitochondria. Hum. Mol. Genet. 2011, 20:1197-1211.
65. Shibayama-Imazu T., Okahashi I., Omata K., Nakajo S., Ochiai H., Nakai Y., et al. Cell and tissue distribution and developmental change of neuron specific 14kDa protein (phosphoneuroprotein 14). Brain Res. 1993, 622:17-25.
66. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathol. 2010, 119:7-35.
67. Solano R.M., Casarejos M.J., Menendez-Cuervo J., Rodriguez-Navarro J.A., Garcia de Yebenes J., Mena M.A. Glial dysfunction in parkin null mice: effects of aging. J. Neurosci. 2008, 28:598-611.
68. Song Y.J., Halliday G.M., Holton J.L., Lashley T., O'Sullivan S.S., McCann H., et al. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J. Neuropathol. Exp. Neurol. 2009, 68:1073-1083.
69. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
70. Steele J.C., Richardson J.C., Progressive Olszewski J., Palsy Supranuclear A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch. Neurol. 1964, 10:333-359.
71. Stefanova N., Klimaschewski L., Poewe W., Wenning G.K., Reindl M. Glial cell death induced by overexpression of alpha-synuclein. J. Neurosci. Res. 2001, 65:432-438.
72. Thannickal T.C., Lai Y.Y., Siegel J.M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007, 130:1586-1595.
73. Togo T., Dickson D.W. Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process. Acta Neuropathol. 2002, 104:398-402.
74. Tong J., Boileau I., Furukawa Y., Chang L.J., Wilson A.A., Houle S., et al. Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J. Cereb. Blood Flow Metab. 2011, 31:2065-2075.
75. Tong J., Fitzmaurice P., Furukawa Y., Schmunk G.A., Wickham D.J., Ang L.C., et al. Is brain gliosis a characteristic of chronic methamphetamine use in the human?. Neurobiol. Dis. 2014, 67:107-118.
76. Tong J., Furukawa Y., Sherwin A., Hornykiewicz O., Kish S.J. Heterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain. Neurobiol. Dis. 2011, 41:458-468.
77. Tong J., Wong H., Guttman M., Ang L.C., Forno L.S., Shimadzu M., et al. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain 2010, 133:172-188.
78. Tu P.H., Galvin J.E., Baba M., Giasson B., Tomita T., Leight S., et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 1998, 44:415-422.
79. Verkhratsky A., Rodriguez J.J., Parpura V. Astroglia in neurological diseases. Future Neurol. 2013, 8:149-158.
80. Verkhratsky A., Rodriguez J.J., Steardo L. Astrogliopathology: A central element of neuropsychiatric diseases?. Neuroscientist. 2014, 20:576-588.
81. Vila M., Jackson-Lewis V., Guegan C., Wu D.C., Teismann P., Choi D.K., et al. The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 2001, 14:483-489.
82. Wakabayashi K., Hayashi S., Yoshimoto M., Kudo H., Takahashi H. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol. 2000, 99:14-20.
83. Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto M., Takahashi H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett. 1997, 239:45-48.
84. Wakabayashi K., Yoshimoto M., Tsuji S., Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 1998, 249:180-182.
85. Wenning G.K., Jellinger K.A. The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathol. 2005, 109:129-140.